Misirlioglu Hasan Cem, Coskun-Breuneval Mehtap, Kucukpilakci Bulent, Ugur Vahide Isil, Elgin Yesim, Demirkasimoglu Taciser, Kara Sakire Pinar, Ozgen Aytul, Sanri Ergun, Guney Yildiz
Department of Radiation Oncology, Ankara Oncology Hospital, Ankara, Turkey E-mail :
Asian Pac J Cancer Prev. 2014;15(20):8871-6. doi: 10.7314/apjcp.2014.15.20.8871.
Postoperative chemoradiotherapy (CRT) of gastric carcinoma improves survival among high- risk patients. This study was undertaken to analyse long-term survival probability and the impact of certain covariates on the survival outcome in affected individuals.
Between January 2000 and December 2005, 244 patients with gastric cancer underwent adjuvant radiotherapy (RT) in our institution. Data were retrieved retrospectively from patient files and analysed with SPSS version 21.0.
A total of 244 cases, with a male to female ratio of 2.2:1, were enrolled in the study. The median age of the patients was 52 years (range, 20-78 years). Surgical margin status was positive or close in 72 (33%) out of 220 patients. Postoperative adjuvant RT dose was 46 Gy. Median follow-up was 99 months (range, 79-132 months) and 23 months (range, 2-155 months) for surviving patients and all patients, respectively. Actuarial overall survival (OS) probability for 1-, 3-, 5- and 10-year was 79%, 37%, 24% and 16%, respectively. Actuarial progression free survival (PFS) probability was 69%, 34%, 23% and 16% in the same consecutive order. AJCC Stage I-II disease, subtotal gastrectomy and adjuvant CRT were significantly associated with improved OS and PFS in multivariate analyses. Surgical margin status or lymph node dissection type were not prognostic for survival.
Postoperative CRT should be considered for all patients with high risk of recurrence after gastrectomy. Beside well-known prognostic factors such as stage, lymph node status and concurrent chemotherapy, the type of gastrectomy was an important prognostic factor in our series. With our findings we add to the discussion on the definition of required surgical margin for subtotal gastrectomy. We consider that our observations in gastric cancer patients in our clinic can be useful in the future randomised trials to point the way to improved outcomes.
胃癌术后放化疗可提高高危患者的生存率。本研究旨在分析受影响个体的长期生存概率以及某些协变量对生存结果的影响。
2000年1月至2005年12月期间,244例胃癌患者在我院接受了辅助放疗。数据从患者病历中回顾性获取,并使用SPSS 21.0版进行分析。
本研究共纳入244例患者,男女比例为2.2:1。患者的中位年龄为52岁(范围20 - 78岁)。220例患者中72例(33%)手术切缘状态为阳性或接近阳性。术后辅助放疗剂量为46 Gy。存活患者和所有患者的中位随访时间分别为99个月(范围79 - 132个月)和23个月(范围2 - 155个月)。1年、3年、5年和10年的精算总生存(OS)概率分别为79%、37%、24%和16%。精算无进展生存(PFS)概率按相同连续顺序分别为69%、34%、23%和16%。在多因素分析中,美国癌症联合委员会(AJCC)I - II期疾病、胃次全切除术和辅助放化疗与OS和PFS改善显著相关。手术切缘状态或淋巴结清扫类型对生存无预后意义。
对于所有胃癌切除术后复发风险高的患者,应考虑术后放化疗。除了众所周知的预后因素如分期、淋巴结状态和同步化疗外,胃切除术类型在我们的系列研究中是一个重要的预后因素。基于我们的研究结果,我们加入了关于胃次全切除术所需手术切缘定义的讨论。我们认为我们在本临床胃癌患者中的观察结果在未来的随机试验中可能有助于指明改善结局的方向。